Background Addition of oxaliplatin to adjuvant 5-FU has significantly improved the disease-
free survival and served as the first line adjuvant chemotherapy in advanced colorectal …

Patient-derived tumor organoids (PDOs) currently represent important modeling tools in pre-
clinical investigation of malignancies. Organoid cultures conserve the genetic and …

Purpose Oxaliplatin-based chemotherapy is a standard treatment for advanced colorectal
cancer (CRC) patients. However, chemoresistance-induced resistance is an essential cause …

Background We propose a new approach for designing personalized treatment for
colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with …

Abstract Background Patient-derived organoids (PDOs) from advanced colorectal cancer
(CRC) patients could be a key platform to predict drug response and discover new …

There is no effective method to predict chemotherapy response and postoperative prognosis
of colorectal cancer liver metastasis (CRLM) patients. Patient‐derived organoid (PDO) has …

Background The inability to predict treatment response of colorectal cancer patients results
in unnecessary toxicity, decreased efficacy and survival. Response testing on patient …

As an emerging technology in precision medicine, the patient-derived organoid (PDO)
technology has been indicated to provide novel modalities to judge the sensitivity of …

Oxaliplatin-based chemotherapy, such as FOLFOX, is the first-line therapy for advanced
colorectal cancer (CRC) or metastatic CRC patients. However, the partial response of …

Colorectal cancer (CRC) is one of the most prevalent malignant tumors of the digestive tract
worldwide. Despite notable advancements in CRC treatment, there is an urgent requirement …